Clinical Trial Update: Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

View source ↗

Summary

This clinical trial update describes evaluating a switch from intravenous to subcutaneous vedolizumab for inflammatory bowel disease, including Crohn's disease …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD) | Status: ACTIVE_NOT_RECRUITING